46 related articles for article (PubMed ID: 10229643)
1. Sites of elimination and pharmacokinetics of recombinant [131I]lepirudin in baboons.
Meiring SM; Lötter MG; Badenhorst PN; Bucha E; Nowak G; Kotzé HF
J Pharm Sci; 1999 May; 88(5):523-9. PubMed ID: 10229643
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the postglomerular renal metabolism of lepirudin in healthy volunteers.
Kautzleben M; Stein G; Sperschneider H; Nowak G
Thromb Res; 2004; 113(3-4):187-95. PubMed ID: 15140582
[TBL] [Abstract][Full Text] [Related]
3. Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis.
Willey ML; de Denus S; Spinler SA
Pharmacotherapy; 2002 Apr; 22(4):492-9. PubMed ID: 11939684
[TBL] [Abstract][Full Text] [Related]
4. Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant.
Salmela B; Joutsi-Korhonen L; Saarela E; Lassila R
Thromb Res; 2010 Jun; 125(6):538-44. PubMed ID: 20181379
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers.
Marbet GA; Verstraete M; Kienast J; Graf P; Hoet B; Tsakiris DA; Silling-Engelhardt G; Close P
J Cardiovasc Pharmacol; 1993 Sep; 22(3):364-72. PubMed ID: 7504125
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure.
Pöschel KA; Bucha E; Esslinger HU; Nörtersheuser P; Jansa U; Schindler S; Nowak G; Stein G
Kidney Int; 2000 Dec; 58(6):2478-84. PubMed ID: 11115081
[TBL] [Abstract][Full Text] [Related]
7. Lepirudin dosing in dialysis-dependent renal failure.
Wittkowsky AK; Kondo LM
Pharmacotherapy; 2000 Sep; 20(9):1123-8. PubMed ID: 10999507
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics study of recombinant hirudin in the plasma of rats using chromogenic substrate, ELISA, and radioisotope assays.
Jiang SY; Jiao J; Zhang TT; Xu YP
PLoS One; 2013; 8(6):e64336. PubMed ID: 23785400
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic studies with recombinant hirudin in dogs.
Nowak G; Markwardt F; Fink E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):70-4. PubMed ID: 2459035
[TBL] [Abstract][Full Text] [Related]
10. In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera.
Hassan M; Refai E; Andersson M; Schnell PO; Jacobsson H
Nucl Med Biol; 1994 Aug; 21(6):865-72. PubMed ID: 9234336
[TBL] [Abstract][Full Text] [Related]
11. Determination of the dosage of recombinant hirudin to inhibit arterial thrombosis in baboons.
Kotzé HF; Lamprecht S; Van Wyk V; Roodt JP; Badenhorst PN
J Pharm Sci; 2000 May; 89(5):579-85. PubMed ID: 10756323
[TBL] [Abstract][Full Text] [Related]
12. Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban.
Gray E; Harenberg J;
J Thromb Haemost; 2005 Sep; 3(9):2096-7. PubMed ID: 16102117
[No Abstract] [Full Text] [Related]
13. Displacement of fibrin-bound thrombin by r-hirudin precludes the use of 131I-r-hirudin for detecting pulmonary emboli in the rabbit.
Rubens FD; Ross-Ouellet B; Dennie C; Coates G; Kinlough-Rathbone RL; Hatton MW
Thromb Haemost; 1994 Aug; 72(2):232-8. PubMed ID: 7831658
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution and pharmacokinetics of transgenic pig-produced recombinant human factor IX (rhFIX) in rats.
Chang CH; Chou TK; Yang CY; Chang TJ; Wu YH; Lee TW
In Vivo; 2008; 22(6):693-7. PubMed ID: 19180993
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of r-hirudin in renal impairment.
Nowak G; Bucha E; Gööck T; Thieler H; Markwardt F
Thromb Res; 1992 Jun; 66(6):707-15. PubMed ID: 1519229
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and partial thromboplastin time after intravenous recombinant hirudin variant-2 in rhesus monkeys.
Liu XW; Song HF; Tang ZM; Zhao K; Zhu BZ; Wang LP; Zhang Y
Acta Pharmacol Sin; 2002 Sep; 23(9):842-6. PubMed ID: 12230955
[TBL] [Abstract][Full Text] [Related]
17. The pharmacology of recombinant hirudin, a new anticoagulant.
Meyer BH; Luus HG; Müller FO; Badenhorst PN; Röthig HJ
S Afr Med J; 1990 Sep; 78(5):268-70. PubMed ID: 2392724
[TBL] [Abstract][Full Text] [Related]
18. Comparison of iodine-131 OIH and technetium-99m MAG3 renal imaging in volunteers.
Taylor A; Eshima D; Fritzberg AR; Christian PE; Kasina S
J Nucl Med; 1986 Jun; 27(6):795-803. PubMed ID: 2940350
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue.
van Iersel T; Stroissnig H; Giesen P; Wemer J; Wilhelm-Ogunbiyi K
Thromb Haemost; 2011 Feb; 105(2):302-12. PubMed ID: 21103657
[TBL] [Abstract][Full Text] [Related]
20. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats.
Freund M; Cazenave JP; Courtney M; Degryse E; Roitsch C; Bernat A; Delebassée D; Defreyn G; Maffrand JP
Thromb Haemost; 1990 Apr; 63(2):187-92. PubMed ID: 2363120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
